Polyphor AG – SIX:POLN.SW
Polyphor AG stock price today
Polyphor AG stock price quarterly change
Polyphor AG stock price yearly change
Polyphor AG key metrics
Market Cap | N/A |
Enterprise value | 10.25M |
P/E | -0.45 |
EV/Sales | 6.23 |
EV/EBITDA | -0.17 |
Price/Sales | 11.22 |
Price/Book | -3.02 |
PEG ratio | -0.01 |
EPS | -5.77 |
Revenue | 1.64M |
EBITDA | -57.48M |
Income | -61.50M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -3724.83% |
Oper. margin | -3594.2% |
Gross margin | 99.54% |
EBIT margin | -3594.2% |
EBITDA margin | -3496.59% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePolyphor AG stock price history
Polyphor AG stock forecast
Polyphor AG financial statements
| Jun 2018 | 1.63M | -12.53M | -765.71% |
|---|---|---|---|
| Jan 2019 | 2.51K | -16.32M | -650411.87% |
| Mar 2019 | 2.51K | -16.32M | -650411.87% |
| Jun 2019 | 2.51K | -16.32M | -650411.87% |
| Dec 2019 | 92767939 | 37.66M | 40.6% |
|---|---|---|---|
| Jun 2020 | 57656787 | 28.10M | 48.74% |
| Dec 2020 | 46770283 | 33.27M | 71.15% |
| Jun 2021 | 26046961 | 32.14M | 123.42% |
| Jun 2018 | -10.99M | 510.72K | 37.59M |
|---|---|---|---|
| Jan 2019 | -14.00M | 344.70K | -36.58K |
| Mar 2019 | -14.00M | 344.70K | -36.58K |
| Jun 2019 | -14.00M | 344.70K | -36.58K |
Polyphor AG alternative data
| Aug 2023 | 52 |
|---|---|
| Sep 2023 | 52 |
| Oct 2023 | 52 |
| Nov 2023 | 52 |
| Dec 2023 | 52 |
| Jan 2024 | 52 |
| Feb 2024 | 52 |
| Mar 2024 | 52 |
| Apr 2024 | 52 |
| May 2024 | 52 |
| Jun 2024 | 52 |
| Jul 2024 | 52 |
Polyphor AG other data
| Patent |
|---|
Grant Utility: Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof Filling date: 31 May 2017 Issue date: 1 Feb 2022 |
Grant Utility: Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof Filling date: 31 May 2017 Issue date: 1 Feb 2022 |
Application Filling date: 6 Oct 2021 Issue date: 27 Jan 2022 |
Application Filling date: 12 Nov 2018 Issue date: 16 Sep 2021 |
Application Filling date: 20 Feb 2018 Issue date: 24 Jun 2021 |
Grant Utility: Beta-hairpin peptidomimetics Filling date: 23 Mar 2016 Issue date: 10 Nov 2020 |
Application Filling date: 18 Jun 2020 Issue date: 8 Oct 2020 |
Grant Filling date: 6 Apr 2016 Issue date: 4 Aug 2020 |
Grant Filling date: 27 Dec 2013 Issue date: 28 Jul 2020 |
Application Filling date: 8 Apr 2020 Issue date: 23 Jul 2020 |
-
What's the price of Polyphor AG stock today?
One share of Polyphor AG stock can currently be purchased for approximately $1.67.
-
When is Polyphor AG's next earnings date?
Unfortunately, Polyphor AG's (POLN.SW) next earnings date is currently unknown.
-
Does Polyphor AG pay dividends?
No, Polyphor AG does not pay dividends.
-
What is Polyphor AG's stock symbol?
Polyphor AG is traded on the SIX under the ticker symbol "POLN.SW".
-
What is Polyphor AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Polyphor AG?
Shares of Polyphor AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Polyphor AG have?
As Jul 2024, Polyphor AG employs 52 workers.
-
When Polyphor AG went public?
Polyphor AG is publicly traded company for more then 7 years since IPO on 15 May 2018.
-
What is Polyphor AG's official website?
The official website for Polyphor AG is polyphor.com.
-
Where are Polyphor AG's headquarters?
Polyphor AG is headquartered at Hegenheimermattweg 125, Allschwil, BASEL-LANDSCHAFT.
-
How can i contact Polyphor AG?
Polyphor AG's mailing address is Hegenheimermattweg 125, Allschwil, BASEL-LANDSCHAFT and company can be reached via phone at +41 61 567 16 00.
Polyphor AG company profile:
Polyphor AG
polyphor.comSIX
52
Biotechnology
Healthcare
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.
Allschwil, BASEL-LANDSCHAFT 4123
:
ISIN: CH0106213793
CUSIP: H63556106
